Synthetic t cell receptors for enhancing memory (STEM) t cells using new transmembranes and signaling domains
The development of synthetic T cell receptors with new transmembrane and signaling domains addresses the limitations of existing CARs, improving T cell persistence and safety, and enhancing the therapeutic efficacy of CAR-T cell therapy for cancer treatment.
Patent Information
- Application Number
- PCT/US2024/034872
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-20
- Filing Date
- 2024-06-20
- Publication Date
- 2024-12-26
AI Technical Summary
Current CAR-T cell therapy for cancer treatment faces challenges such as disease relapse, severe toxicities, and limited T cell persistence due to the limitations of existing chimeric antigen receptors (CARs) in terms of stability, specificity, and cytokine production, which affect therapeutic efficacy and safety.
Development of synthetic T cell receptors with enhanced stability and specificity using new transmembrane and signaling domains, including hinge and transmembrane domains derived from T cell receptors and cytokine receptors, to improve T cell signaling, activation, and persistence, while minimizing cytokine production.
The enhanced CARs improve therapeutic potential and safety by promoting longer T cell persistence, reducing toxicities, and maintaining antitumor immunity, thereby enhancing the long-term cancer cure rates and reducing relapse.
Smart Images
Figure US2024034872_26122024_PF_FP_ABST
Abstract
Citation Information
Cited By
Chimeric antigen receptor targeting CD26 and application thereof
CN121591916A
Membrane-anchored cytokine fusion proteins and uses thereof
WO2026161764A1